Home
Empowering Precision Medicine
Finding all relevant mutations in a single test
- Targeted complete next generation sequencing of any locus or (trans)gene of interest
- Detection of all SNVs and structural variants
- Identification of all gene fusions and clinically relevant mutations in cancer genes
- Kits & services
"We use TLA to sequence gene fusions and other rearrangements in genes of interest. We have been impressed by the quality of TLA and Cergentis' work and are testing the use of identified breakpoint sequences as targets for personalised minimal residual disease tests."
"TLA is a highly efficient method for mapping the insertion site of any transgene.”
"Working with the team at Cergentis has allowed us to add an extra dimension to the analysis of our stable cell lines. Their understanding of our needs combined with the reliability and reproducibility of TLA analysis has resulted in a number of successful projects."
"TLA analysis has proven to be very useful to quality control genetically engineered cell lines”
"Thank you so much. Data about the structural changes in our patient are very clear. Really powerful technology!”
"TLA has become an indispensable tool to characterize transgene insertion events and complex gene targeting approaches."
"Unknown translocation partners that drive expression of oncogenes as consequence of cryptic or previous unidentified chromosomal rearrangements were identified in T-cell leukemia patients using Targeted Locus Amplification.”
"TLA outperforms traditional methods used in CHO cell line characterisation and provides higher resolution and sensitivity.”
"Cergentis quickly determined transgene insertion for three out of three lines along with providing information on deletions and rearrangements in chromosomal DNA at the site. The service was quick, accurate and reasonably priced, and reports were complete and helpful.”
"Targeted Locus Amplification enables fast identification of new chromosomal rearrangements and genomic breakpoint sequences in human T-ALL and unraveled a higher complexity of chromosomal translocations of known T-ALL oncogenes as thus far appreciated.”
